ArticleScientific reports2022
Neurodevelopmental outcomes in very low birthweight infants with retinopathy of prematurity in a nationwide cohort study.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Impact of anti-VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta-analysis.Acta ophthalmologica · 2026Pooled it
- Epidemiology and treatment trends of retinopathy of prematurity: a multi-center study involving four Asian centers and one European center (2016-2023).Japanese journal of ophthalmology · 2026Article
- Association between base excess levels and clinical outcomes among very low birth weight infants: a multicenter birth cohort study in South Korea.Clinical and experimental pediatrics · 2026Article
- Retinopathy of Prematurity and Neurodevelopmental and Quality-of-Life Outcomes at 10 Years of Age.American journal of perinatology · 2026Article
- Risk factors and prevalence of retinopathy of prematurity in very low birth weight preterm infants: a systematic review and meta-analysis.Translational pediatrics · 2026Article
- The social and economic burden of retinopathy of prematurity: screening, treatment, and health policy perspectives in a transnational narrative review.Frontiers in pediatrics · 2026Review
- Article
- Correlation between histologic chorioamnionitis and severe retinopathy of prematurity.Pediatric research · 2025Article
- The aftermath of retinopathy of prematurity blindness.Eye (London, England) · 2025Article
- Early medical risks to language development in extremely preterm infants.Journal of perinatology : official journal of the California Perinatal Association · 2025Article
- Strategies to support language development in neonatal intensive care unit: a narrative review.Clinical and experimental pediatrics · 2024Article
- Retinopathy of prematurity and neurodevelopmental outcome and quality of life at 10 years of age.Research square · 2024Article
- Hypothyroxinemia and weight velocity in preterm infants.Journal of pediatric endocrinology & metabolism : JPEM · 2024Article
- Antenatal Magnesium Sulfate Is Not Associated With Improved Long-Term Neurodevelopment and Growth in Very Low Birth Weight Infants.Journal of Korean medical science · 2023Article
- Neurodevelopmental outcomes of preterm infants.Clinical and experimental pediatrics · 2023Article
- Korean Developmental Screening Test for Infants and Children (K-DST): development, applications, and implications for future early childhood development interventions.Clinical and experimental pediatrics · 2023Article
- Long-Term Visual Prognosis of Patients Following Lens-Sparing Vitrectomy for Stage 4A Retinopathy of Prematurity.International journal of molecular sciences · 2023Article
- In-hospital growth and long-term neurodevelopmental outcomes of very low birth weight infants.Frontiers in pediatrics · 2023Article
- Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: A systematic review and meta-analysis.Frontiers in pediatrics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a nationwide prospective cohort of Korean infants with very low birthweights (VLBW, birth weight < 1500 g) from 70 neonatal intensive care units of the Korean Neonatal Network, we investigated neurodevelopmental outcomes in preterm infants with retinopathy of prematurity (ROP) from 2132 infants with VLBW who had undergone developmental assessments at 18-24 months of corrected age. Motor, cognitive, or language delay was determined using developmental scores that were less than 1 standard deviation from the average. Comparative analyses and multivariate regression analyses were performed to validate the association between ROP or its treatment and developmental delay. Motor (52.8% vs. 36.3%), cognitive (46.8% vs. 31.6%), and language delays (42.5% vs. 28.4%) were noted more frequently in infants with ROP than in those without ROP; this was statistically significant (all P < 0.001). Multivariate analyses showed that motor and cognitive delays were significantly associated with ROP. There were no remarkable differences between the neurodevelopmental outcomes and the treatment modalities (laser photocoagulation, anti-vascular endothelial growth factor injection, or both) for ROP, and both stratification and multivariate regression analyses confirmed no significant association between anti-vascular endothelial growth factor therapy and neurodevelopmental delay. As ROP is significantly associated with poor neurodevelopmental outcomes independent of extreme prematurity, neurodevelopmental functions should be given attention in infants with ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.